“Bimekizumab Efficacy and Safety Through 3 Years in Patients With Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT”. SKIN The Journal of Cutaneous Medicine 10, no. 2 (March 10, 2026): s762. Accessed May 2, 2026. https://skin.dermsquared.com/skin/article/view/4081.